CDC Releases New Recommendations for Serogroup B Meningococcal Vaccination

The Centers for Disease Control and Prevention (CDC) recently released new recommendations for the MenB-FHbp vaccine for preventing serogroup B meningococcal disease.

Patients who are 16 to 23 years of age and not at a high risk for meningococcal disease are recommended to receive the 2-dose series of the MenB-FHbp to be administered at 0 and 6 months.

For patients from 10 to 25 years of age who are at an increased risk for meningococcal disease, the CDC recommends the 3-dose vaccine series to be administered at 0, 1 or 2, and 6 months. In addition, the 3-dose series is recommended during meningococcal disease outbreaks.

The update to the recommendations was based on the April 2016 US Food and Drug Administration approved changes to the dosage and administration of the vaccine, which included both the 2-dose and 3-dose series.

—Melissa Weiss

Reference:

Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine — Advisory Committee on Immunization Practices, 2016. CDC. https://www.cdc.gov/mmwr/volumes/66/wr/mm6619a6.htm. Published May 19, 2017. Accessed May 23, 2017.